How Gene Editing and Genomic Research Are Transforming Modern Medicine
Commentary
by Hayley F.
Over the past two decades, genetics and genomics have evolved from highly specialized research fields into some of the most transformative areas of modern science. Advances in DNA sequencing, computational biology, and gene-editing technologies are rapidly changing how scientists understand disease, inheritance, and even the biological foundations of human life itself.
One of the most significant developments in recent years has been the advancement of CRISPR-Cas9 gene-editing technology. Originally discovered as part of a bacterial immune defense system, CRISPR now allows researchers to precisely modify DNA sequences within living organisms. Scientists are exploring its use in treating inherited disorders such as sickle cell disease, cystic fibrosis, and beta thalassemia, conditions historically managed only through supportive care or high-risk treatments.
In 2023 and 2024, several countries approved the first CRISPR gene editing-based therapy for the treatment of inherited blood diseases including sickle cell disease and transfusion-dependent beta thalassemia. This is a breakthrough for genomics medicine because these therapies edit the patients’ own stem cells to boost the production of functional hemoglobin, which reduces or eventually eradicates the need for blood transfusions. Many scientists considered this as a first significant leap in translating gene editing technology from experimental research to the clinic on such a large scale.
Similarly, technologies for genomic sequencing have been rapidly developed over the years and have become much faster, cheaper and accessible to researchers and healthcare professionals.
The whole genome sequencing, which used to take years and billions of money for sequencing the Human Genome Project, can now be done within a few days, at a greatly reduced cost. This has provided new opportunities for precision medicine that can be applied as treatments customized for patients’ own genomes.
In addition, AI is playing an increasing role in improving genomic analysis, such as identifying mutations associated with specific diseases, predicting the three-dimensional structures of proteins, and making sense of the enormous volumes of genomic data. The development of this technique, in combination with other technological advances, can assist physicians in oncology to perform more precise cancer treatment based on their patients’ tumor’s genomic profile.
Meanwhile, a newly emerging area, epigenetics which concerns how environmental factors might affect gene expression without directly changing the DNA sequences has received considerable attention. We now understand that life experiences such as stress, diet, exposure to pollution, lifestyle and others can affect the patterns in which our genes function. This challenge the traditional notion about genetics by highlighting the interaction between biology and the environment.
On the other hand, all these developments also raise serious ethical and social issues. Privacy regarding genetics information, unfair access to genomic treatments, modification of embryos and designer genes are still major debates in both scientific community and politics and the potential benefits of CRISPR therapy and the ethical implications for human society are subject to strict regulations and public consultation.
Current developments in genetics and genomics demonstrate how rapidly biological science is evolving. What once seemed impossible, editing disease-causing mutations, sequencing entire genomes in days, or predicting protein structures through artificial intelligence, is increasingly becoming part of modern medicine.
We can anticipate that future research on genetics and genomics will revolutionize human comprehension of diseases, inheritances and their own biology; the genome is gradually turning into a read-and in some ways, an editable system that continues to define the future of science and medicine.
References
- Doudna, J., Charpentier, E. “The New Frontier of Genome Engineering with CRISPR-Cas9.” Science (2014).
- National Human Genome Research Institute, Human Genome Project Overview.
- U.S. FDA approvals of CRISPR-based therapies for sickle cell disease and beta thalassemia (2023).
- DeepMind. “AlphaFold Protein Structure Prediction.” Nature (2021).
- National Institutes of Health, Precision Medicine Initiative.
Art by Stockcake
About the Author
Hayley is a student writer interested in the intersection of science, medicine, and storytelling.